Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease.
about
Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and CognitionPotential therapeutic effects of neurotrophins for acute and chronic neurological diseasesCombotherapy and current concepts as well as future strategies for the treatment of Alzheimer's diseaseDrug repositioning approaches for the discovery of new therapeutics for Alzheimer's diseasePhosphodiesterases as therapeutic targets for Alzheimer's disease.Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.Enhancing cognition before clinical symptoms of dementia.Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington's disease.Pleiotropic locus for emotion recognition and amygdala volume identified using univariate and bivariate linkage.Specific serotonergic denervation affects tau pathology and cognition without altering senile plaques deposition in APP/PS1 mice.Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease.Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease.PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic DiseaseReduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression.A new player in the "synaptopathy" of Alzheimer's disease - arc/arg 3.1.Modulating nitric oxide signaling in the CNS for Alzheimer's disease therapy.Brain-Derived Neurotrophic Factor in Alzheimer's Disease: Risk, Mechanisms, and Therapy.Mechanisms Involved in the Remyelinating Effect of Sildenafil.Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.Pharmacological Rescue of Long-Term Potentiation in Alzheimer Diseased SynapsesLoss of Endothelial Nitric Oxide Synthase Promotes p25 Generation and Tau Phosphorylation in a Murine Model of Alzheimer's Disease.Modulation of the ASK1-MKK3/6-p38/MAPK signalling pathway mediates sildenafil protection against chemical hypoxia caused by malonate.Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels.Selective inhibition of phosphodiesterase 5 enhances glutamatergic synaptic plasticity and memory in mice.Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.Phosphodiesterase type 5 and cancers: progress and challenges.From Age-Related Cognitive Decline to Alzheimer's Disease: A Translational Overview of the Potential Role for Phosphodiesterases.Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer's Disease.Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer's disease.Cilostazol improves hippocampus-dependent long-term memory in mice.Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study.Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease.A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice.Sildenafil Decreases BACE1 and Cathepsin B Levels and Reduces APP Amyloidogenic Processing in the SAMP8 Mouse.Long-lasting neuroprotective effect of sildenafil against 3,4-methylenedioxymethamphetamine- induced 5-hydroxytryptamine deficits in the rat brain.A novel synthetic phosphodiesterase 5 inhibitor, KJH-1002, ameliorates scopolamine-induced cognitive impairments in mice by activating the cGMP/CREB signaling pathway and attenuating oxidative damage.SMMDB: a web-accessible database for small molecule modulators and their targets involved in neurological diseases
P2860
Q26746978-F534EECA-3B3E-4DCE-8970-6B1BEEDFB019Q26771954-C29021DF-CBAE-4893-B583-FE61F8F40FA1Q26827281-4EE16D02-95C8-4949-A994-CADCBBAAA9D7Q26829899-46218F71-AA3E-4A88-BDEB-04B6625437ACQ27024122-52704658-ED0C-41F7-9D88-5FF7E217B5F8Q28279704-448CE7A4-E0EA-440F-AF1D-ADE53CD21979Q33624262-FAD5A548-5353-4D25-9B02-E8E81AA418ADQ34708103-98710554-0F6B-4602-BEA8-E340918A7FB8Q34989074-619711F6-64D3-466C-B7A0-207D0398E630Q35040160-DD918299-07B3-4CD9-A4E4-872131A9A8DBQ35053378-A46F8CD6-2425-48DD-B915-7BE08E41CAF4Q36142843-1885E19E-96B4-40BE-95F9-7ECA2FDEE5FFQ36279313-9DBB2BB7-731D-4B5B-AEAE-B414D34068D7Q37053929-B69D652C-36A3-43C4-BD74-1CD599B16295Q37689973-CD431421-C806-49D1-8220-272F33825922Q38081344-2EB043FF-3B89-47E4-BEC7-74010A1AB202Q38126948-A9C1CB98-696C-4816-A96C-7300399C42C5Q38263685-2848898A-9E4F-43C6-94CD-FCAFE2FEABE6Q38641811-F655F7CC-889C-4588-8863-AD3C37FE2CF5Q38643963-23DB39F8-C4D1-49AA-9334-29347455A166Q39093414-C36EF7F6-5F9D-4041-9D92-05D265809297Q39416237-7A2AECBA-3863-4E19-95E9-688D371FDB99Q39759995-BDA3BE3F-FEA3-4400-B848-ADBC307D540DQ40238471-7DCF1732-CCA1-480C-9D2A-94C02F597651Q42437731-A6FECC0D-678F-42D6-BEFC-BCECE438992FQ45305673-B6191EC2-24A7-4169-A371-C788FEF90F35Q47171803-033111C3-93CB-4BDF-A364-CA1854CE45F0Q47611446-4606F571-27CB-4F1A-A611-183FCB78046AQ47784347-DF237283-032A-47E9-A26A-41F4241AED75Q47784892-65191EE8-7E89-42BB-93AD-6CD8B9BAE88EQ47925672-44026995-737B-46CC-8018-22ECAC462369Q48394157-C54D6B3F-48BB-40B3-A365-757DDAF5B8EDQ48419390-C4FFE58D-D674-4901-B2BF-EC9CB5AE2944Q48557521-25CFC115-0349-4625-8CDC-DE928AEAD94BQ48636699-10FB39AD-6298-4AA9-A90C-8350D6F5E2DDQ48878720-036CE3BD-DBE7-418C-B96F-B04ED172FB31Q54977667-084243BA-8395-44F6-96E7-C380B0BBED2DQ58743091-B53E71FF-C671-4CDF-AC7A-5C524DC013D7
P2860
Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Sildenafil restores cognitive ...... model of Alzheimer's disease.
@ast
Sildenafil restores cognitive ...... model of Alzheimer's disease.
@en
type
label
Sildenafil restores cognitive ...... model of Alzheimer's disease.
@ast
Sildenafil restores cognitive ...... model of Alzheimer's disease.
@en
prefLabel
Sildenafil restores cognitive ...... model of Alzheimer's disease.
@ast
Sildenafil restores cognitive ...... model of Alzheimer's disease.
@en
P2093
P2860
P50
P1476
Sildenafil restores cognitive ...... e model of Alzheimer's disease
@en
P2093
A Ricobaraza
C García-Barroso
J M Pérez-Roldán
P2860
P304
P356
10.1111/J.1476-5381.2011.01517.X
P407
P577
2011-12-01T00:00:00Z